The GTF2F2 antibody targets the General Transcription Factor IIF subunit 2 (GTF2F2), a key component of the RNA polymerase II transcription machinery. GTF2F2. also known as TFIIF, forms a heterodimer with GTF2F1 to regulate transcription initiation and elongation. This complex facilitates the recruitment of RNA polymerase II to promoters, stabilizes its binding, and promotes transition from initiation to elongation phases by interacting with other transcription factors like TFIIB and TFIIH. GTF2F2 is essential for accurate gene expression and is implicated in cellular processes requiring dynamic transcriptional regulation.
Antibodies against GTF2F2 are widely used in research to study its expression, localization, and functional interactions in normal and diseased states. They are employed in techniques such as Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP) to explore transcriptional mechanisms, DNA repair pathways, and cell cycle regulation. Dysregulation of GTF2F2 has been observed in cancers and neurodegenerative disorders, making these antibodies valuable tools for investigating transcriptional abnormalities in disease models. Additionally, they aid in characterizing protein-protein interactions within the transcription preinitiation complex, providing insights into fundamental gene regulation processes. Commercial GTF2F2 antibodies are typically validated for specificity across human, mouse, and rat samples.